Lymphomatous polyposis is a rare primary gastrointestinal lymphoma. It morphologically and immunohistochemically resembles mantle cell lymphoma, with which it shares a disappointing response rate and duration following conventional anthracyclin-containing combination chemotherapy, with a short median survival and virtually no long-term survivors. We report the use of high-dose chemotherapy with autologous stem cell transplantation in second partial remission in three patients with lymphomatous polyposis treated at the Royal Marsden Hospital. All patients achieved a complete response, and one patient remains well and disease-free 64 months following transplantation and 76 months after diagnosis.
Multiple lymphomatous polyposis (MLP) is a rare primary gastrointestinal (GI) B cell lymphoma characterised by polypoid tumours resulting from accumulation of lymphoma tissue in the mucosa and submucosa of various segments of the gastrointestinal tract. Cornes 1 first used the term multiple lymphomatous polyposis (MLP) in 1961 to describe a morphologically heterogeneous group of 27 cases displaying this growth pattern, making up 13% of his cases of primary GI lymphoma. As entities such as immunoproliferative small intestinal disease (IPSID), enteropathyassociated T cell lymphoma (EATL) and mucosa-associated lymphoid tissue (MALT) lymphoma were recognised and separated, Blackshaw 2 identified a group of tumours of B cell lineage with 'centrocytic' morphology, frequently involving the ileocaecal area and with late spread to non-GI sites, associated with a poor prognosis. Isaacson and colleagues 3 definitively separated MLP from other forms of primary gastrointestinal lymphoma such as MALT lymphomas, and characterised it as a distinct entity. Since MLP shares the morphological, immunohistochemical and cytoCorrespondence: Dr D Cunningham, The Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK Received 13 November 1997; accepted 25 January 1998 genetic characteristics, as well as the clinical behaviour of mantle cell lymphoma (MCL), it has been regarded as its intestinal form by some groups.
MCL is the newly ascribed term for the group of small monoclonal B cell proliferations previously termed centrocytic lymphoma in the Kiel classification, diffuse or follicular small cleaved cell lymphoma in the Working Formulation or mantle zone lymphoma (MZL), intermediate lymphocytic lymphoma (ILL) or lymphocytic lymphoma of intermediate differentiation (IDL) in the United States. MCL is included within the broadly defined group of lowgrade lymphomas, [4] [5] [6] of which it makes up approximately 10%, typically presenting in males over 60 at an advanced stage. The tumour cells arise from the follicular mantle zone and are mostly small, slightly irregular cleaved cells arranged in a pattern that varies between frankly nodular/follicular to diffuse. A blastoid subtype with large transformed cells and a poorer prognosis has been described. 6, 7 Characteristically, cells are sIg + , CD5 + , CD 20 + , CD 43 + , CD 10 − and CD 23 − , and carry a t(11;14) chromosomal translocation leading to overexpression of cyclin D1, resulting in excessive proliferation. Although classified as low grade or indolent lymphomas, mantle cell lymphomas appear to have a significantly worse prognosis than other indolent non-Hodgkin lymphomas. [6] [7] [8] Median duration of first remission is approximately 1 year, and median survival was reported as 36 months in the SWOG study 8 and in a recent review of 524 MCL patients treated with combination chemotherapy, 9 while the ELTF reported median survival of 42 months. 6 Patients with the blastoid subtype, low sodium or albumin at presentation 7 or with poor risk according to the International Index 6 had a significantly worse prognosis. No conventional chemotherapy regimen has been shown to be superior in the treatment of MCL patients, although a retrospective analysis showed a survival advantage in good-risk patients treated with an anthracycline-containing regimen. 6 Conventional chemotherapy does not seem to achieve cures in this disease, and there are no plateaus on the survival curves. In view of this, more intensive chemotherapy regimens, including highdose chemotherapy with autologous transplant have been explored, with preliminary data suggesting improved disease-free and overall survival. 9 Some research protocols including the European Intergroup Trial in MCL are cur-rently investigating the role of early high-dose treatment (HDT) in this condition.
Lymphomatous polyposis patients frequently relapse with widespread disease in a pattern similar to mantle cell lymphoma following an initial response to chemotherapy, with second remissions difficult to achieve and short-lived. High-dose treatment appears to be a rational investigational approach in patients whose expected remissions are likely to be short-lived.
We report a patient with lymphomatous polyposis who received high-dose therapy and autologous stem cell transplantation in second partial remission at the RMH, and remains well and in complete remission 64 months later. We review the pertinent literature and clinical courses of the two other patients transplanted at the RMH, who also achieved complete remission, but who relapsed after 16 and 12 months, respectively. 1b 1a Figure 1 Endoscopic (a) and radiological (b) appearance of lymphomatous polyposis. The polyps are seen protruding into the bowel lumen and leading to contrast filling defects on the abdominal CT scan, which also demonstrates the characteristic bowel wall thickening.
Case reports

Patient 1
A 47-year-old man presented July 1991 with a 2-month history of diarrhoea and progressive weight loss and a normal clinical examination. On colonoscopy, he was found to have diffuse involvement of the large bowel with polyps. These were biopsied, and histology was reported as B cell centrocytic, WF E NHL diffusely infiltrating the lamina propria. Review of the histology in the light of modern classification and terminology confirmed that this tumour should be considered to be MLP. CT scan showed only retrocrural and para-aortic lymphadenopathy. Bone marrow aspirate and trephine were clear of disease. Lactate dehydrogenase (LDH) was 169 IU, ␤ 2-microglobulin (B2M) 2.7 mg/l, albumin 26 g/l. He was randomised to the PACEBOM arm in the BNLI CHOP vs PACEBOM study, and received six courses between August and November 1991, achieving a good PR.
In March 1992, he relapsed in the bowel, lymph nodes of the left axilla, mediastinum, retroperitoneum and mesentery, liver and spleen. The bone marrow was involved. LDH was 802 IU and B2M 3.9 mg/l. The patient started standard CHOP chemotherapy and intrathecal methotrexate CNS prophylaxis. Following two cycles he achieved a second PR and the marrow was cleared of disease. No further response was seen after two further CHOP cycles, and the patient was considered to be at high risk of rapid progression. Autologous bone marrow was harvested in July 1992. One year following the original diagnosis, he received high-dose chemotherapy with BEAM (BCNU 300 mg/kg day −6, etoposide 200 mg/m 2 day −5 to −2, Ara-C 200 mg/m 2 bd days −5 to −2, melphalan 140 mg/kg day −1) with simultaneous i.v. methylprednisolone, followed by reinfusion of 2.25 × 10 8 unpurged nucleated cells/kg. He tolerated the treatment well, with no relevant non-haematologic toxicity. CT evaluation 3 and 6 months following high-dose treatment showed further reduction in the previously enlarged lymph node groups, and a scan in June 1995 was unchanged. Colonoscopy confirmed complete clearance of polyps, and biopsies were negative. He remains well, with no clinical or laboratory evidence of disease, 64 months after high-dose treatment and 76 months following the original diagnosis.
Patient 2
A 59-year-old man presented with a short history of rectal bleeding, was found on colonoscopy to have a large sigmoid tumour along with other polypoid lesions, and underwent sigmoid colectomy. On histological examination, two distinct pathologies were identified. The sigmoid tumour was a moderately differentiated Dukes B sigmoid adenocarcinoma with no evidence of dissemination. Multiple biopsies from the polypoid lesions were reported as intermediate-grade diffuse small cleaved cell NHL, WF E. Review of histology slides confirmed MCL morphology and immunophenotype. Staging showed enlargement of pericolic and pelvic lymph nodes, and examination of perioperative biopsies revealed splenic but not hepatic involve-ment. The bone marrow was clear of disease. LDH was 174 IU, B2M 2.1 mg/l and albumin was 24 g/l. The patient achieved complete remission (CR) in April 1993 after six courses of standard CHOP chemotherapy. In August 1994 he was found to have relapsed on routine colonoscopy and biopsy. Staging CT scans showed small bilateral cervical and axillary, as well as mediastinal and retroperitoneal lymphadenopathy. The spleen (on CT criteria) and BM were involved. LDH was 609 IU. He received six courses of EPIC chemotherapy (etoposide 100 mg/m 2 days 1-4, prednisolone 100 mg days 1-5, ifosfamide 1 g/m 2 days 1-5 and cisplatin 60 mg/m 2 day 10 every 3 weeks) between October 1994 and January 1995, achieving a partial remission (PR), with small volume residual disease in the mediastinum, left axilla and retroperitoneum. Disease in the bone marrow had cleared. PBSC were harvested and MBE chemotherapy subsequently administered in March 1995 (BCNU 300 mg/kg day −6, etoposide 300 mg/m 2 days −5 to −2, melphalan 140 mg/kg day −1). The graft contained 5.71 x 10 8 nucleated cells. The patient tolerated the procedure well, and restaging 3 months after high-dose showed that CR had been achieved. He remained well until August 1995, when he developed rapidly enlarging splenomegaly and cervical lymphadenopathy. A CT scan also showed central mediastinal and para-aortic lymph nodes, and there was histological evidence of lymphomatous involvement of bone marrow and liver. A splenectomy was performed, since the spleen contained the bulk of disease, followed by four different salvage regimens. The disease remained refractory to all treatments, except for a minor response to DHAP chemotherapy lasting only 2 months. It disseminated to new sites including the CNS and he died on 25 January 1997, 22 months following high-dose treatment.
Patient 3
A 50-year-old man presented with abdominal pain and diarrhoea without blood or mucus in November 1994. Physical examination was unremarkable. On colonoscopy, numerous polyps were found throughout the large bowel, and a massive fungating polypoid tumour was seen. At laparotomy, the tumour mass was causing intussusception of the ileocaecal valve and was removed. Numerous grape-sized polypoid tumours were seen or palpated throughout the small and large bowel. Following recovery from surgery, the patient was referred to this hospital, and first seen in December 1994. There was no clinically detectable disease. The LDH was 329 IU, B2M 2.3 mg/l and albumin was 33 g/l. A CT scan showed small volume lymphadenopathy in the mesentery and retroperitoneum but no other disease. Bone marrow aspirate and trephine were negative. The patient had eight courses of CHOP chemotherapy between December 1994 and May 1995, and achieved a complete remission after six courses, as evidenced by normal endoscopy up to the terminal ileum and resolution of the CT scan abnormalities. At the end of this treatment, stem cells were harvested in the event of a recurrence necessitating further intensive chemotherapy followed by autologous transplant. He remained well until March 1996 when he developed abdominal pain and diarrhoea, initially associated with night sweats. A colonoscopy confirmed relapse of lymphomatous polyposis with multiple lesions in the large bowel. A CT scan showed marked thickening of the duodenum and proximal duodenum, with numerous polyps in the small bowel. Large volume mesenteric lymph nodes, which had previously been enlarged but which had normalised were noted. Salvage chemotherapy was DHAP (cisplatin 100 mg/m 2 day 1, Ara-C 2 g/m 2 bd day 2, dexamethasone 40 mg days 1-4). Following two courses of treatment, he achieved a good partial response with near resolution of all lymph node sites and decreased thickening of the duodenum. He was admitted for MBE chemotherapy (melphalan 140 mg/m 2 , BCNU 300 mg/m 2 , etoposide 300 mg/m 2 for 4 days) in July 1996. The peripheral stem cells, harvested a year earlier, were reinfused on 8 August 1996. He tolerated the treatment well, with grade 2 nephrotoxicity and ototoxicity as the only side-effects from treatment. A CT scan in October 1996 showed complete response and a repeat CT scan on 31 January 1997 and clinical examination showed continued complete response 6 months after high-dose treatment. He remained well and asymptomatic, but staging CT scan at 1 year following transplant showed that the disease had recurred in the small bowel and mesenteric lymph nodes with no further spread. Salvage treatment has been initiated.
Discussion
Due to its relative rarity and recent definition as a separate entity, only limited data exist on natural history and response to chemotherapy in lymphomatous polyposis. The most extensive report published by O'Briain and colleagues 10 included 24 patients. In this series, median age at presentation was 61 years, with a strong male preponderance, and the most frequent symptoms were weight loss, mild iron deficiency and fatigue. Patients often had an ileocaecal mass, and polyposis involving various segments of the gastrointestinal tract. Approximately one-third of patients had involvement of peripheral lymph nodes, bone marrow and peripheral blood, respectively. Median survival was under 3 years in spite of intensive conventional chemotherapy. Out of another series of 12 patients, 11 five died 5-22 months following diagnosis (median survival 9 months).
To our knowledge, high-dose chemotherapy and autologous transplantation has been used in only four patients 12 with clinical presentations suggestive of lymphomatous polyposis (although confirmatory immunohistochemistry data were available on only two patients). In that group, one patient initially rather unusually presented with retroorbital lymphoma, and two had BM involvement at diagnosis. All four patients received anthracycline-containing chemotherapy, followed by abdominal radiotherapy or orbital radiotherapy in two cases, and achieved a partial remission. They proceeded immediately to high-dose treatment (cyclophosphamide/TBI in two cases and CBV/TBI in the other two). Three patients achieved CRs lasting 35, 21 and 11 months at the time of publication, the fourth patient remained in stable PR for 21 months.
Here, we report three patients who initially presented with lymphomatous polyposis extensively involving colon and small bowel (patient 3), and little evidence of disease spread beyond local-regional lymph nodes, and who achieved PR or CR after conventional chemotherapy. Four, 10 and 16 months later they progressed or relapsed in multiple sites, with features of high-risk disease according to the International Index. Patients 1 and 2 had bone marrow involvement by lymphoma at relapse, which cleared after salvage chemotherapy. All three patients had residual disease at the time of transplantation, and high-dose treatment was given to consolidate the remission and prevent rapid disease progression. One patient relapsed 6 months later with chemoresistant disease, and died 22 months following transplant, and another was found to have an asymptomatic recurrence on routine CT scan 12 months following highdose therapy and is undergoing further treatment. The first patient described remains well and disease-free 64 months following transplant.
These data, together with the study by Mahe and colleagues 12 suggest that complete and lasting remissions can be achieved by HDT in MLP both in patients initially failing to achieve a CR with anthracycline-containing chemotherapy and in patients progressing rapidly following intensive conventional chemotherapy.
MLP is similar to MCL both morphologically and immunophenotypically, and the bcl-1/PRAD-1 gene rearrangement driving cellular proliferation by overexpression of cyclin D1 is found in both entities. 13 Their natural histories overlap. Lymphomatous polyposis often presents with predominant gastrointestinal involvement and symptoms, but on staging, extension beyond the gastrointestinal tract and regional nodes is often found, and on relapse or progression, dissemination to distant lymph nodes and extralymphatic organs is as frequent as gastrointestinal tract progression.
In a careful and well documented series of longitudinally followed-up cases, MCL in turn was shown to frequently involve the gastrointestinal tract, especially in cases with blastoid transformation. 7 In nine out of 20 patients who had a full autopsy, blastoid transformation had been proven by biopsy before death. Seven of these nine patients had gastrointestinal tract involvement at autopsy, but only one had known lymphomatous polyposis at presentation. MCL and MLP may be the two ends of a clinical spectrum ranging from predominantly mucosal to nodal lymphoma. Pals et al 14 suggested that the mucosal tropism of lymphomatous polyposis may be due to expression of the mucosal homing receptor ␣ 4 ␤ 7 , which is absent on morphologically identical nodal lymphomas. The aggressive clinical behaviour and poor prognosis of both these entities justifies a search for more efficient treatments, and high-dose therapy with autologous transplantation should be considered in these patients.
